The American College of Physicians is urging policymakers to expand access to obesity treatment and healthy foods while investing in prevention and research.
A fragmented system built on isolated metrics like BMI and A1C fails to capture the full picture of metabolic health and limits our ability to manage it effectively.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Association Scientific Sessions meeting.
A new Nomi Health report found that GLP-1 use and spending among adolescents rose sharply from 2022 to 2025, raising concerns about future costs for self-insured employers.
Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue.
FDA approval for Eli Lilly’s oral GLP-1 drug, Foundayo, comes about three months after Novo Nordisk launched its Wegovy pill. While clinical trial results for both daily pills showed comparable weight reduction, Lilly’s pill offers patients a slight dosing advantage.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Structure Therapeutics’ aleniglipron, a once-daily oral GLP-1 drug, led to an average 16% weight loss measured at 44 weeks. Based on these results, the biotech is preparing for Phase 3 testing expected to begin in the second half of this year.
Petrelintide posted Phase 2 results showing tolerability comparable to a placebo, but average weight loss that was less than what analysts expected. The Zealand Pharma drug, in development under a partnership with Roche, is a peptide engineered to activate the amylin receptor.
Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.
A monthly injectable GLP-1 drug from Pfizer’s $10 billion Metsera acquisition is now on track for a Phase 3 program spanning 10 pivotal studies this year. While Pfizer’s pipeline spans internally developed and in-licensed assets for other targets, the pharma company says the Metsera drug is the foundation for its obesity strategy pursuing monotherapies and combination treatments.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
AstraZeneca’s deal with CSPC Pharmaceutical Group includes a Phase 1-ready obesity drug that hits the same targets as Eli Lilly’s obesity drug Zepbound, but with monthly dosing. The new collaboration builds on an existing drug R&D relationship between the two companies.
Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.
Beyond weight reduction and long-term maintenance of weight loss, the FDA decision for oral Wegovy covers use of the once-daily pill for reducing the risk of major cardiovascular events. Novo Nordisk expects the Wegovy tablet will launch in early January.
YaoPharma’s once-daily oral GLP-1 drug is currently in Phase 1 testing. The license agreement gives Pfizer global rights to the small molecule, which it envisions as part of potential drug combinations.
The Trump administration’s new deal lowers prices and expands access to GLP-1 drugs, but experts argue far broader reforms are needed to address high prescription drug costs overall.